2022
DOI: 10.1182/blood-2022-171039
|View full text |Cite
|
Sign up to set email alerts
|

Obinutuzumab Induced ITP:a Case Report

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
4
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(5 citation statements)
references
References 0 publications
0
4
1
Order By: Relevance
“…We did not observe OIAT after repeat administrations of obinutuzumab; however, in most other cases in the literature, anti-CD20 was discontinued or switched to rituximab [ 4 , 6 ] or thrombocytopenia recurred after subsequent obinutuzumab administrations [ 5 ]. In addition to thrombocytopenia, Walter et al [ 7 ] reported the possible association of OIAT with coagulopathy; however, other observations with OIAT [ 1 – 5 , 8 ] including our own experience did not share the similar finding.…”
Section: Discussioncontrasting
confidence: 56%
“…We did not observe OIAT after repeat administrations of obinutuzumab; however, in most other cases in the literature, anti-CD20 was discontinued or switched to rituximab [ 4 , 6 ] or thrombocytopenia recurred after subsequent obinutuzumab administrations [ 5 ]. In addition to thrombocytopenia, Walter et al [ 7 ] reported the possible association of OIAT with coagulopathy; however, other observations with OIAT [ 1 – 5 , 8 ] including our own experience did not share the similar finding.…”
Section: Discussioncontrasting
confidence: 56%
“…The optimal management of obinutuzumab‐induced thrombocytopenia is unclear, as the cause is often unclear. Analogous to ITP, steroids and IVIg have been associated with responses whereas platelet transfusions may not be effective 2,5 . Two recent cases of severe thrombocytopenia were treated with thrombopoietin receptor agonist 6 .…”
Section: Discussionmentioning
confidence: 99%
“…Analogous to ITP, steroids and IVIg have been associated with responses whereas platelet transfusions may not be effective. 2,5 Two recent cases of severe thrombocytopenia were treated with thrombopoietin receptor agonist. 6 As shown in case 4 and other studies, switching from obinutuzumab to rituximab may avoid the recurrence of thrombocytopenia.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations